Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.
Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
Laurie H. GlimcherBenjamin Levine EbertLaurie H. Glimcher will step down as Dana-Farber Cancer Institute president and CEO on Oct. 1.
Pasi A. Jänne received the GO2 for Lung Cancer’s 2024 Bonnie J. Addario Lectureship Award.
Jonathan Chernoff and William G. KaelinWilliam G. Kaelin Jr., physician, scientist, and Nobel laureate, was recognized at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction.
For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.
More than a decade ago, Glenn Begley and Lee Ellis published a paper with astounding findings: of 53 “landmark” studies, only six, or 11%, were reproducible, even with the same reagents and the same protocols—and even, sometimes, in the same laboratory—as the original study.
Over 50 research papers that list top leaders of Dana-Farber Cancer Institute among authors are implicated in an investigation of allegations of data manipulation.
It’s a divorce everyone has an opinion on.
Mark Agnel Frederick DawsonCigall KadochMichelle MonjeMemorial Sloan Kettering Cancer Center has named three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
Elad Sharon was named clinical and translational director of the Immunotherapy Toxicity Service at Dana-Farber Cancer Institute. Sharon will work to build out the research and clinical components of the program.
